Rovista 20mg Tablet
Rovista 20mg Tablet (Rosuvastatin), a synthetic lipid-lowering agent for oral administration. Rovista 20mg Tablet is bis[(E)-7-[4-(4-fluorophenyl)- 6-isopropyl-2- [methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)- 3,5-dihydroxyhept-6-enoic acid] calcium salt. Rovista 20mg Tablet molecular formula for rosuvastatin calcium is (C22H27FN3O6S)2Ca. Rovista 20mg Tablet should be prescribed with caution in patients with predisposing factors for myopathy/rhabdomyolysis. Such factors include: renal insufficiency, hypothyroidism, personal or family history of hereditary muscular disorders, previous history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate, alco hol abuse, age >70 years, situations where an increase in plasma levels may occur, concomitant use of fibrates. In such patients the risk of treatment should be considered in relation to possible benefit and clinical monitoring is recommended. If creatinine kinase levels are significantly elevated at baseline (>5xULN) treatment should not be started. – There is an increase in serum transaminases [AST (SGOT) o r ALT (SGPT)] with HMG-CoA reductase inhibitors, including Rovista 20mg Tablet. It is recommended that liver enzyme tests be performed before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (e.g., semiannually) thereafter. If an increase in ALT or AST of >3 times ULN persist, reduction of dose or withdrawal of Rovista 20mg Tablet is recommended.
This medication is used as an adjunct with diet changes and exercise in treating primary hypercholesterolemia (high cholesterol level in the blood) or mixed dyslipidemia (elevations in Low Density Lipoprotein cholesterol and triglyceride levels, often accompanied by low levels of HDL cholesterol).
Side effect :
Patients using this medication may commonly experience weakness, dizziness (lightheadedness), myalgia (muscle pain), diabetes, headaches, stomachache, fatigue, and immune-mediated necrotizing myopathy.
When not use :
It is contraindicated in severe kidney impairment, active liver disease (elevated serum transaminases). the use of 40 mg dose of this drug in Asian patients & patients with risk factors of myopathy or rhabdomyolysis like moderate kidney impairment.